Want to see JP:4883 full AI Analyst Report?
Total Valuation
Modalis Therapeutics Corporation has a market cap or net worth of ¥3.64B. The enterprise value is ¥369.62M.
Market Cap¥3.64B
Enterprise Value¥369.62M
Share Statistics
Modalis Therapeutics Corporation has 113,634,094 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding113,634,094
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Modalis Therapeutics Corporation’s return on equity (ROE) is -0.77 and return on invested capital (ROIC) is -78.17%.
Return on Equity (ROE)-0.77
Return on Assets (ROA)-0.73
Return on Invested Capital (ROIC)-78.17%
Return on Capital Employed (ROCE)-0.78
Revenue Per Employee0.00
Profits Per Employee-126.63M
Employee Count17
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Modalis Therapeutics Corporation is ―. Modalis Therapeutics Corporation’s PEG ratio is 0.81.
PE Ratio―
PS Ratio0.00
PB Ratio1.55
Price to Fair Value1.55
Price to FCF-2.04
Price to Operating Cash Flow0.00
PEG Ratio0.81
Income Statement
In the last 12 months, Modalis Therapeutics Corporation had revenue of 0.00 and earned -2.15B in profits. Earnings per share was -27.86.
Revenue0.00
Gross Profit0.00
Operating Income-2.21B
Pretax Income-2.15B
Net Income-2.15B
EBITDA-2.21B
Earnings Per Share (EPS)-27.86
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Modalis Therapeutics Corporation pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.16
52-Week Price Change-60.00%
50-Day Moving Average33.02
200-Day Moving Average48.00
Relative Strength Index (RSI)44.94
Average Volume (3m)2.23M
Important Dates
Modalis Therapeutics Corporation upcoming earnings date is Nov 11, 2026, Before Open (Confirmed).
Last Earnings DateAug 10, 2026
Next Earnings DateNov 11, 2026
Ex-Dividend Date―
Financial Position
Modalis Therapeutics Corporation as a current ratio of 21.46, with Debt / Equity ratio of 10.96%
Current Ratio21.46
Quick Ratio21.46
Debt to Market Cap0.00
Net Debt to EBITDA1.27
Interest Coverage Ratio-788.80
Taxes
In the past 12 months, Modalis Therapeutics Corporation has paid 1.54M in taxes.
Income Tax1.54M
Effective Tax Rate>-0.01
Enterprise Valuation
Modalis Therapeutics Corporation EV to EBITDA ratio is -0.68, with an EV/FCF ratio of -0.71.
EV to Sales0.00
EV to EBITDA-0.68
EV to Free Cash Flow-0.71
EV to Operating Cash Flow-0.72
Balance Sheet
Modalis Therapeutics Corporation has ¥3.02B in cash and marketable securities with ¥270.00M in debt, giving a net cash position of ¥2.75B billion.
Cash & Marketable Securities¥3.02B
Total Debt¥270.00M
Net Cash¥2.75B
Net Cash Per Share¥24.16
Tangible Book Value Per Share¥36.15
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Modalis Therapeutics Corporation is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast-5.66%